DaVita Inc. (DVA) Earnings Call Transcript & Summary

August 3, 2021

New York Stock Exchange US Health Care Health Care Providers and Services earnings 43 min

Earnings Call Speaker Segments

Jim Gustafson

executive
#1

Thanks, and good morning to all of you joining our Q2 conference call. We're grateful that you keep following what's happening with our business. This is Jim Gustafson speaking — I serve as Vice President of Investor Relations. With me on the line today are Javier Rodriguez, who is our CEO, and Joel Ackerman, our CFO. Be aware that statements we might make on this call could be forward-looking ones under federal securities laws. Known and unknown risks and uncertainties apply to each such statement, and those factors might make actual outcomes differ materially from what those forward-looking statements describe. If you want more information about those risks and uncertainties, take a look at our Q1 earnings press release along with our SEC filings — that includes our latest annual report on Form 10-K, later quarterly reports on Form 10-Q, and any additional filings we submit to the SEC. What we say that looks ahead rests on information we have right now, and we have no intention, and take on no obligation, to revise those statements unless the law demands it. We also want to point out that some non-GAAP financial measures will come up during this call. You can find a reconciliation between those non-GAAP measures and the closest comparable GAAP measures in the earnings press release we filed with the SEC, which is also posted on our website. At this point I'll hand things over to Javier Rodriguez.

Javier Rodriguez

executive
#2

Thanks, Jim, and good afternoon, everyone. It's a pleasure to speak with you today regarding our robust second-quarter results, our financial outlook for 2021, and the latest news around what we're doing to reshape Kidney Care. I'd like to open with a clinical achievement. For patients with kidney failure who qualify, receiving a kidney transplant represents the optimal treatment path. Over the years, DaVita has put substantial effort into assisting our patients in obtaining access to transplantation via education and hands-on support so they can join the transplantation waitlist and remain on it. The accumulated effect is significant. In December of last year, we shared a milestone: 100,000 DaVita patients have undergone a transplant since 2000. To push the transplantation cause further forward, DaVita is working together with the National Kidney Foundation on a pilot lasting one year, designed to boost health equity in kidney transplantation, with living donors as the central focus. Boosting living donor transplants widens access to transplantation by raising organ availability, which has constrained how many transplants get performed each year; this pilot delivers highly personalized, hands-on information to patients and families pursuing a kidney transplant from a living donor. We're eager to learn from this pilot, enhance health equity in kidney transplant, and keep leading the way in helping our patients obtain kidney transplants. Now to the newest COVID update. Over the past several months, we've achieved tremendous progress in fighting the COVID-19 pandemic. New COVID infections among our patients kept falling substantially through the final week of June, dropping over 95% versus the peak in early January. Yet, just like the rest of the nation, we've begun noticing a rise during the past few weeks. As of last week, measured on a rolling 7-day average, new infections remain more than 90% below the peak. So far, our mortality has stayed low in absolute terms, since we believe our vaccinated patients enjoy greater protection against severe COVID cases. We keep teaching our patients about vaccine benefits in order to lower vaccine hesitancy, and we stay confident in the policies and procedures we've built to protect our patients and our teammates while they're receiving our care; now I'll move to our financial results for the second quarter. We posted strong numbers for both operating income and earnings per share. Our margins grew as we kept managing costs while providing quality care. Consequently, we achieved 6% year-over-year growth in adjusted operating income along with 35% year-over-year growth in adjusted earnings per share. Our free cash flow proved especially robust this quarter, and we keep giving cash back to shareholders via stock buybacks; now that the first half of the year is finished, we're raising the midpoint of guidance for the entire year. Let me shift to an update on our progress with Integrated Kidney Care efforts, also called IKC. When it comes to value-based care for kidney disease patients, momentum is building, and it looks like we've hit an inflection point. Our long-held view has been that if dialysis care were coordinated with the wider health needs of CKD and ESKD patients, we could improve outcomes while also bringing down total health care costs. Over the years, we've taken part in many smaller programs and pilots so we could build our integrated care capabilities and get a clearer read on the economics; our belief is that we've now arrived at the moment where we can move into the next phase of integrated care's evolution. You may ask, why now? The movement toward value-based care isn't a new phenomenon, whether in Kidney Care or elsewhere in health care. So what has shifted to make a scaled business workable at this point? There are a few reasons. To start, as Medicare Advantage has expanded, payers are seeking creative approaches to handle the growing count of ESKD patients who select MA plans. Such patients are typically more complex than the typical MA patient and ought to gain from care management tailored to them. Next, CMS launched payment models in Kidney Care not long ago. Starting in January of next year, we're getting ready to work alongside nephrologists in as many as 12 markets to take part in CKCC voluntary programs. Taking part in the CKCC model will likewise give us operational scale across more geographies for entering other value-based arrangements. Finally, we've grown more confident in our ability to deliver clinical and economic value at scale, and we've leaned into our readiness to accept risk; our view is that we're well positioned to win in integrated care thanks to our strong partnership with nephrologists, our frequent and consistent patient interactions, a wide Kidney Care platform covering multiple modalities of care settings, and a clinical data set plus analytics we use to design and build clinical interventions that support our patients holistically. We've shown a demonstrated record of bettering patient outcomes, coordinating care, and reducing costs for patients in risk arrangements. In our ESCOs, for instance, we produced non-dialysis cost savings in the high single digits, which meant savings rates more than double the industry average across the life of the program; through our special needs plan, we've managed to reduce mortality by 23% compared with other patients in the same center and county. To give you a clearer picture of the business's scale, as of today, roughly 10% of our U.S. dialysis patients are in value-based care arrangements where DaVita bears responsibility for managing the total cost of care. That amounts to nearly $2 billion in annual medical costs under management; on top of that, we hold various other forms of value-based care arrangements with payers that give us economic incentives for improving quality and lowering costs. Looking ahead to 2022, our Integrated Kidney Care segment should grow to twice its current size — that applies to patient counts, risk arrangements, and assets under management alike. We anticipate as well that the count of CKD lives covered under risk will rise sharply during 2022. To get ready for that expansion, we're in the process of expanding our clinical staff while continuing to develop our support infrastructure. Given this spending, together with lagging cost-savings effects from our care model and revenue recognition, we anticipate posting a net operating loss of $120 million during 2021 within our U.S. ancillary segment; that result lines up with the OI headwinds tied to IKC growth that we flagged early in the year, and naturally it's baked into our full-year guidance. Doubling the business in the coming year might bring about an additional operating loss of $50 million during 2022 in our ancillary segment. We anticipate meaningful gains in financial results starting in 2023, when savings begin to be recognized from the new contract signed in 2021 and 2022. Looking out beyond 5 years, we think our IKC business may turn into a durable source of considerable operating income growth. At present, roughly 200,000 dialysis patients nationwide receive our services. More than $12 billion went toward health care services delivered outside the dialysis facility, covering hospitalization costs, outpatient procedures, and physician services. Beyond that, we see a chance to manage care for upstream CKD patients who aren't currently dialyzing at our centers. If we assume responsibility for the total cost of care for over half of our dialysis patients plus other CKD patients, at a margin ranging from low to single digit, we think this may represent a substantial financial opportunity; in short, the entire health care industry has discussed value-based care for many years. We're thrilled for DaVita to take the lead; with that, I'll hand the call over to Joel.

Joel Ackerman

executive
#3

Appreciate that, Javier. We delivered a robust quarter in spite of the ongoing operational hurdles that COVID has created, driven mainly by solid RPT results and our ongoing cost discipline; operating income for the quarter came in at $490 million, and earnings per share reached $2.64. Within our Q2 results is a net COVID headwind of roughly $35 million, which is comparable to the impact we experienced in Q1. That reflects mostly the effect of excess mortality on volumes along with higher PPE costs, partly offset by sequestration relief plus lower spending on travel and meetings. Now on to volume; treatments per day for Q2 rose 0.4% versus Q1. Excess mortality dropped substantially in Q2, going from about 3,000 in Q1 to under 500 in Q2. At this stage, we're cautiously optimistic that the worst has passed, though we're watching closely for any potential effects from the Delta variant, particularly in areas of the country where vaccination rates are lower. Over the longer term, we still expect to get back to pre-pandemic treatment growth levels, with an added tailwind coming from mortality rates that are below normal. U.S. dialysis revenue per treatment was up sequentially by nearly $6 this quarter, largely because of the usual seasonal gains as patients satisfy their coinsurance and deductible obligations. We also benefited from favorable shifts in government rate and mix, among them the growing share of patients covered by Medicare Advantage. On a combined basis, patient care costs and G&A expense per treatment stayed roughly flat from quarter to quarter. Patient care costs came down sequentially, mainly from lower labor costs. G&A edged up, driven largely by charitable contributions and higher personnel costs. As we anticipated, our U.S. dialysis and lab DSOs fell by about 6 days in Q2 relative to Q1, mostly from collections on the temporary billing holds tied to the first-quarter winter storms. Most of the storms' effect on DSO and cash flow will unwind in Q2, though a smaller ongoing benefit could persist through the remainder of the year. In the second quarter, we recorded a gain of roughly $9 million on one of our DaVita Venture Group investments, which landed in the other income line of our P&L. We hold a small stake in Miromatrix Medical, which recently became public. That investment was worth $23 million at quarter end. Looking ahead, we'll mark it to market each quarter. Let me now move to a few updates on the balance of this year and some early thinking about 2022. As Javier noted, we are lifting our 2021 guidance ranges as follows: adjusted earnings per share of $8.80 to $9.40; adjusted operating income of $1.8 billion to $1.875 billion; and free cash flow of $1 billion to $1.2 billion; in addition, we now anticipate that our 2021 effective tax rate on income attributable to DaVita will land between 24% and 26%, which is below the 26% to 28% range we shared at the start of the year. The updated outlook we've provided doesn't factor in what a major fourth wave of COVID could do later in the year. There are 2 potential headwinds worth flagging for the back half of the year. The first one is COVID. Our expectation remains that excess mortality's effect will be greater across the back half than it was in the first half, because mortality throughout 2021 compounds over time. On top of that, we anticipate a rise in expenses tied to testing, vaccinations and teammate support stemming from the Delta variants. Because of this, we're raising the midpoint for the full-year COVID impact to $170 million, up from $150 million; that works out to a $30 million headwind from COVID across the back half of the year versus the first half. Keep in mind, this sits at the middle of a broad spectrum of possible outcomes, which hinges on how the Delta variant or other variants play out, along with any further COVID mandates. The second item: within our U.S. ancillary segment, we anticipate losses of roughly $70 million during the back half of the year, versus $50 million in the first half; this added loss stems mainly from new value-based care arrangements plus start-up costs tied to the CKCC program, which launches in 2022. Turning to 2022, nothing out of the ordinary is expected among the business's primary drivers, which include RPT, cost per treatment and capital expenditures. That said, we do anticipate pressure on OI growth coming from heavier spending to grow our IKC business, the chance of union activity in 2022 that wasn't present in 2021, and the initial year of depreciation expense tied to our new clinical IT platform, which we've spent the past several years developing. More detailed 2022 guidance will come on a future earnings call. Operator, please open the lines for questions.

Pito Chickering

analyst
#4

To kick things off regarding that IKC you mentioned, the one you discussed in the script with $2 billion in gross revenues that you expect to double in 2022 — could you walk us through how that moves through the P&L, both for the dialysis segments and for other ancillary services? At what point will you start reporting these revenues and costs on the P&L so we can model it? And looking out 5 years, how big do you think this could get? Is that $12 billion figure the one you cited in the script? Also on margins, after Year 1, you assigned a high single-digit margin to the $2 billion for next year, plus additional drag from the $2 billion in new capitated arrangements?

Joel Ackerman

executive
#5

Thanks, Pito. I hope I covered all of that, but please jump in if I missed anything; so to begin, on where it sits in the P&L, we have a segment called strategic initiatives, which splits between U.S. and international. The U.S. portion of strategic initiatives serves as a very good proxy for our IKC P&L. We've streamlined what's in that segment over the past few years as we've exited certain strategic initiatives. And aside from a couple of minor items, everything tied to IKC runs through that line. So when you're thinking about both revenue and operating income, treating the U.S. piece of SIs as a proxy for our IKC business is a very solid approach. That's the first point. As for where this can go over time, look, there are plenty of questions about how many members we can enroll here, what our savings rate can be, how much of that we'll ultimately capture. I think a fairly straightforward way to model it would be to begin with roughly 1/3 of our ESKD population in this — apply a spend per patient, particularly if you're looking a few years out, of $100,000 per patient, and that gives you a medical cost under management; then the question becomes what percentage of medical costs under management do we believe can convert into OI? And I'd say a sensible figure would be somewhere in the low single digits, something comparable to what a typical MA plan would generate as margin; so 1%, 2%, 3%, maybe 4% in that range as a percentage of medical cost under management, I think, is the right way to think about the potential here in the out years. Sorry, Peter, I believe you had a third question that I didn't catch.

Pito Chickering

analyst
#6

Sure. There are several questions bundled together here. I suppose, will you folks start reporting those gross revenues, plus the patients under management? Just assist us in modeling this moving forward too.

Joel Ackerman

executive
#7

Right; so I don't believe — a figure we'd label gross revenue is not something we're going to share. What I think we will share is the amount revenue would total had we applied gross revenue accounting, and that equals the medical cost under management. We've encountered this situation previously. Those sit under DMG. Certain parts of the business used gross accounting while others used net, and we'd report medical costs under management, or a similar term, and that's the $2 billion figure that we — that Javier mentioned during the script.

Pito Chickering

analyst
#8

All right, and a brief second question about treatment growth specifically. Could you share how many patients were on hand when 1Q wrapped up and when 2Q wrapped up? What I'm after is a sense of how treatment growth looks across the back half of the year, now that excess mortality and COVID are, with luck, in the rearview. And should we take it that things hold around where they sit now, would modeling treatment growth turning positive in the fourth quarter be reasonable?

Joel Ackerman

executive
#9

Sure. Well, in my view the metric worth watching isn't patients — it's treatments per day. And here's the encouraging part; let me take you through it. To start with the encouraging part: on a per-day basis, treatments rose in Q2 relative to Q1. Looking at this sequentially, rather than year over year, should give you a stronger model; measured that way, per-day treatments climbed roughly 400 between Q1 and Q2. Several factors are at play in that figure. So let me lay them out for you. To begin with the encouraging part: starts of new-to-dialysis treatment are still robust; we've fielded questions before about what COVID did to the CKD population, and what we keep observing is robust new-to-dialysis treatment — admissions. So at present we aren't sensing any strain there. Regarding Q2 versus Q1, Q2 got a lift from the storms that hit in Q1. You'll recall that the storms — those from Uri — pushed treatment volume lower in Q1. As a result, the Q2 comparison gained from that. Even so, a handful of factors dragged on the quarter. To begin with, acute volumes declined, which is what you'd anticipate as the pandemic eased in Q2 relative to Q1. Next, excess mortality stayed above normal. It was far under the level seen in Q1. The figure fell from roughly 3,000 to under 500, yet it was still above normal. And lastly, treatment-day mix in Q2 worked against us; Tuesday, Thursday, and Saturday carry fewer treatments than Monday, Wednesday, and Friday do, and that created about a 50 basis — that amounted to roughly a 50 basis point headwind in Q2 versus Q1. So to put it briefly, the encouraging part is that we're once again in a position where treatments are expanding from one quarter to the next. New-to-dialysis admissions are still robust. Even so, some noise persists in the figures.

Justin Lake

analyst
#10

I'd like to dig deeper into value-based care. So, regarding what Pito asked, it would be helpful if those figures could be shared with us. And will that cover only government programs? Or will you be in a position to — will you additionally include any MA value-based contracting — the commercial value-based contracting you have, beyond what exists on the dialysis side?

Joel Ackerman

executive
#11

Yes, Justin, all of that would be covered. MA would be covered, traditional Medicare would be covered, along with anything on the commercial side.

Justin Lake

analyst
#12

Alright. So that figure is entirely profitability. I'm guessing — does dialysis spending get counted in that, or left out? When you mention a margin, is the $60,000 ex-dialysis what you mean? Or do you mean the 90,000, 95,000 figure, which brings dialysis in once you gross up for the $2 billion?

Joel Ackerman

executive
#13

Dialysis is counted in there. So depending on which time period you look at, the patient count would be closer to 100,000 or 90,000.

Justin Lake

analyst
#14

Great. Now, regarding what you brought up during the call — actually, in the press release — about your payer mix shifting somewhat favorably: could you elaborate on commercial volume compared with government?

Javier Rodriguez

executive
#15

Justin, honestly, there isn't much to add. It's somewhat a matter of numerator and denominator. Mortality was higher among Medicare patients. Meanwhile, the commercial side stayed solid, since people truly value their income along with their insurance. As a result, it's proven far more resilient than we expected, so that's the situation we're talking about. A few additional points, Justin, since you raised value-based care and how we figure it for dialysis versus non-dialysis. I believe it matters to run the calculation you're running. You take out the dialysis, and then you must account for the payer/government taking a share of the savings, followed by the nephrologist taking a share of the savings. That's how you arrive at roughly the 1, 2, or 3 percentage that Joel mentioned.

Justin Lake

analyst
#16

All right. Could you also — would you walk me through how much commercial treatment grew during the quarter?

Joel Ackerman

executive
#17

What I can share is that in Q2, commercial mix rose roughly 20 bps compared with Q1.

Justin Lake

analyst
#18

Alright, that's great. And then when it comes to...

Joel Ackerman

executive
#19

Just to remind everyone, during COVID you receive less benefit from that, since your Medicare patients are dying, compared with what you'd see in ordinary circumstances.

Justin Lake

analyst
#20

All right. Then one final item on — you brought up 2022, and I'm sorry if this slipped past me, but regarding the change in tax rate for this year, should we expect it to carry over into 2022? Or would it be fair to treat this as a sensible new tax rate going forward? Alternatively, do we revert to the initial guidance and use that as the tax rate for 2022?

Joel Ackerman

executive
#21

A great deal remains uncertain about how things will unfold. In my view, it makes sense to figure that a portion, perhaps the entirety, of the gain we're getting this year will extend into the following year, though it won't last forever; so for 2022, that's right. As for 2023, I'd say no.

Kevin Fischbeck

analyst
#22

OK, that sounds good. I'd like to explore something — the money you're putting into value-based care. Let me just confirm I understood the figures correctly. My recollection is that you mentioned $120 million for this year, and after that it seemed you mentioned $50 million. Was that $50 million of additional spending, meaning something like $170 million in total? Or were you saying the $120 million drops to $50 million?

Javier Rodriguez

executive
#23

Additional.

Kevin Fischbeck

analyst
#24

So that's on top of what we already have. Alright. When we look at that figure, I'm wondering whether it's calculated after offsets — meaning if you begin earning a 2% margin from value-based care, does that reduce it? Or does it already account for whatever profit might come from that?

Javier Rodriguez

executive
#25

The figure is net.

Kevin Fischbeck

analyst
#26

So the net figure, got it. Next, it seemed as though you mentioned that CKCC was part of that $120 million. Is that correct? And regarding that amount — I suppose I'm just attempting to work through the $120 million to $170 million and the roll off involved there. Is everything accounted for in that?

Joel Ackerman

executive
#27

Correct. Kevin, CKCC won't begin until the start of 2022, however we'll begin putting money in during the back half of the year in preparation for that growth. So it isn't — it's a cost we are incorporating ahead of growth tied to CKCC.

Kevin Fischbeck

analyst
#28

9 All right. Now regarding the quarter-over-quarter growth in enrollment or treatment, I suppose the way to view it, naturally, is that numerous factors both help and hurt that figure. I guess, once things return to normal, how should that figure appear? I guess something like 0.4%, which I take to mean 1.6% on an annualized basis. What's your view — when everything normalizes, what's the volume growth rate? Would it be 2%? Would it be 3%? What would it ultimately be on an annualized basis?

Javier Rodriguez

executive
#29

At the end of the day, Kevin, I believe one point is that you heard from Joel — many distinct dynamics are interacting; on our side, the favorable part is that we are observing what we might call new admissions having settled at pre-COVID levels. Therefore, the strongest evidence available to us at present indicates we will go back to the pre-COVID figures. So I think that's the finest assumption, and we'll update you should that shift.

Kevin Fischbeck

analyst
#30

All right. And from what you're saying, it doesn't seem like labor is much of an issue for you. A lot of businesses out there are voicing concerns about labor-related strain. Could you maybe share a bit about how you're handling that? And then it sounded like you brought up union matters, but I believe what you were referring to was more along the lines of ballot initiatives, correct — not really labor expenses, but rather ballot initiatives that could create pressure in the coming year?

Javier Rodriguez

executive
#31

Yeah. Let me address a few of those. We're not about to sit here and gripe about the strain, but it is definitely present. This marketplace is extremely fluid and fiercely competitive. We keep putting money into a workplace that stands apart, and we see that our teammates derive tremendous satisfaction from the mission behind what we do. Having said that, once again, the marketplace is very fluid. On the second point, yes, what we were referring to was that the union could potentially put forward another ballot. So at this point, sadly, we've had to contend with this every other year. Our hope is that they show a bit more understanding of the reality that we're in a pandemic, and that this isn't a productive way to use resources, but we simply want to keep the conversation going so that nothing catches anyone off guard.

Kevin Fischbeck

analyst
#32

Understood, and this will be my last one. Thinking about how much room there is for growth in value-based care, would you say your approach stands apart from others? Do you expect that to cause movement in market share? Might smaller or mid-sized competitors find it hard to match what you're accomplishing, especially since you're aligned with the payers — meaning you could end up seeing an increase in volume because of it? Is that basically where the whole sector is headed, and since your own move in this direction is pretty similar, would you say you're not really expecting — is the point here mainly revenue and margin rather than picking up share?

Javier Rodriguez

executive
#33

It's a fascinating situation. Looking at it through our lens, we feel our position is quite strong; and naturally, volume and mix involve many moving parts, since how someone reaches us depends on decisions made by the patient, the payer, and the physician. So there's a great deal happening within that set of dynamics. Can everyone along that entire chain truly recognize the worth we deliver? My guess is that eventually the response becomes affirmative, since the results seen in patients will make that case. And things will become visible enough that someone says, "Wow, if staying there means more years of life, if it means getting additional transplants, if it means managing my CKD without landing in the hospital, that's where I'd choose to be." Yet, as you're aware, this doesn't happen overnight. So the way I see it, at this moment I'm not building in any assumption that choices start being made differently until we see how this unfolds further.

Lisa Clive

analyst
#34

Sorry if I overlooked this during the prepared remarks, but what figure did you give for the vaccination rate among your patients? And what about the rate for your teammates? Then a second question: have you been administering third doses to certain patients, since those who are immunocompromised appear not to respond as well to the vaccines when it comes to efficacy? And finally, do you still test patients and teammates ahead of every session? I'm just curious how that will change over the next several quarters.

Javier Rodriguez

executive
#35

All right. Let me take those, and if I skip any of them, please follow up with me. Patients who are fully vaccinated with 2 doses come to roughly 72%. For teammates, it's 68%. We've begun monitoring those who plan to receive a vaccine, and we're seeing somewhere between 1% and 2% who are either considering it or are in their first cycle. As far as I know, there's nothing meaningful regarding the third dosage in our population at this point. I'm aware the physician community is talking about it. So — but I don't have any significant figures on that. And what was that last question of yours?

Lisa Clive

analyst
#36

Regarding the testing.

Javier Rodriguez

executive
#37

When it comes to testing, not every patient was tested, I believe that was part of what you were asking. Our approach is, naturally, we test anybody showing any symptoms. And beyond that, naturally, since our patients consume so much health care, they end up tested far more often — when they visit other physician offices, hospitals, or similar places, they receive tests. So they do get tested at a disproportionate rate, but we only test in the presence of symptoms.

Pito Chickering

analyst
#38

I appreciate you fitting in a few follow-ups. I want to revisit the IKC topic, since the way it's being disclosed has left investors somewhat puzzled. From what I understand as of today, you bring in $2 billion in gross revenues, roughly speaking. Of that, around 50% sits within dialysis costs, while the remaining 50% falls under medical costs — or perhaps other medical costs. So if you mention a margin of 1% to 4%, does that apply to the entire $2 billion? Should we instead frame it as a margin of 2% to 8% on the $1 billion tied to non-dialysis costs?

Joel Ackerman

executive
#39

Both approaches are acceptable. We chose to make the full cost our standard, though doing the math the other way is completely fine as well.

Pito Chickering

analyst
#40

All right, that's great. Now, I'd like to move on to the topic of patient care costs. Clearly, there was a great deal of anxiety about wage inflation during the second quarter. Your cost for each treatment did decline from the prior period, and that came from several different places. However, when I look ahead to patient care costs across the coming 2 years, could you provide some insight into what might generate additional efficiencies, particularly as it pertains to higher center occupancy and changes in the mix of home-based care?

Javier Rodriguez

executive
#41

I'll take that one. Regarding inflation, naturally, we have performed quite well historically. Looking at our CAGR across roughly the past 5 years, I think it sits at approximately 1%, maybe just under that. We therefore consider the available levers very carefully as time goes on; we handle essentially the pharmaceuticals, we handle productivity and, naturally, the wage rate, alongside other categories such as supplies and various miscellaneous items, where we remain extremely attentive. So aside from what happened with COVID, we don't expect those dynamics to shift a great deal. Naturally, PPE costs have risen sharply, and our hope is that this will level off eventually. When it comes to wage inflation, we don't have anything in particular to share; we're simply one more participant in this highly dynamic market, and it seems to be changing very rapidly at the moment. Whether that's a brief phenomenon or something that persists, I can't really speak to the multiyear picture. What I can say is that we are looking hard at every pharmaceutical option to guarantee that our physicians can select their pharmaceutical while obtaining the most favorable price available. So I'm not sure whether I addressed everything you asked. The final piece, I believe, concerned capacity utilization. Naturally, we are monitoring that extremely closely. There was a period when we pursued de novo construction very aggressively. As you're aware, we significantly reduced that pace and now are developing far more home centers, which require considerably less capital; we'll continue keeping that balance in check since we understand patients require the interaction between home and center. That means capacity must be there. And given that we lost approximately 5% of our patients because of COVID, we are examining our portfolio closely to ensure patients can access care and that we don't have centers operating below the appropriate capacity.

Pito Chickering

analyst
#42

All right. Then, at least for the moment, here's a final follow-up from me regarding the IKC. As you grow your penetration among IKC patients, is it reasonable to view the operating income within the dialysis segment as staying flat?

Joel Ackerman

executive
#43

Yeah. I'd say that's reasonable. Our aim in presenting this is to reflect the reality that the business is — these parts aren't standalone, and up to now they've been deeply — they're connected. That's the reason we believe, and we're enthusiastic about, our chance to succeed in IKC, yet we're attempting to show them as though they were separate income statements, so to speak, so you can evaluate how the core historical dialysis business is performing and how the new IKC business is performing.

Pito Chickering

analyst
#44

And then the final item here. Is it reasonable to expect that, as you move into the third quarter results, you'll provide us with extra disclosures in the press release regarding this new segment or division?

Joel Ackerman

executive
#45

We're examining closely what constitutes the appropriate level of disclosure as the IKC business expands, and ensuring that shareholders possess a solid grasp of the business's economics, its progress, the investment, the spending, and so forth. So there's more to come regarding where we settle on that.

Javier Rodriguez

executive
#46

All right, and thanks, Missy. I'll wrap up with a few final points. First, the foundation of what we do remains solid. Second, we're stepping into a thrilling, fast-moving period where we can create substantial value for patients by linking and aligning their care alongside payers, nephrologists and providers. Third, the clinical and economic figures carry real weight, and as is typical with value-based pricing, plenty of work lies ahead to turn the plan into reality. Fourth, should we somehow fail to reach the outcomes we're aiming for, the economic exposure stays structurally capped thanks to termination rights and off-ramps. So to sum up, the potential reward is large while the risk on the downside is contained. Hopefully that gives you a sense of — pardon me, that helps you grasp a bit of how our thinking runs; we appreciate your backing. And we're starting this fresh chapter side by side. Take care, everyone.

Operator

operator
#47

Today's call is now finished. At this point you're free to hang up, and we appreciate your participation.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.